ArticleEBioMedicine2026
Targeting pyruvate kinase M2 (PKM2) reduces T cell pathogenicity in multiple sclerosis.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPyruvate kinase M2 (PKM2) is an enzyme with moonlighting activities that controls murine T cell pro-inflammatory potential in a mouse model of multiple sclerosis (MS). However, no study analysed in detail the expression of PKM2 in human T cell subsets, and whether targeting PKM2 may limit the inflammatory potential of T cells from patients with MS is unknown.
methodsIn this observational, case control study we evaluated the expression of PKM2 in circulating T cells of healthy control individuals (HCs) and patients with MS, as well as its isomerisation in peripheral blood mononuclear cells (PBMCs) from HCs and patients. In parallel, we analysed the impact of targeting PKM2 on the inflammatory profile of T cells from HCs and individuals with MS.
findingsCirculating effector and memory T cells express higher PKM2 levels compared to naïve T cells, and PKM2 expression in such T cell subsets may correlate with age and disease duration in individuals with MS. Among effector/memory T cells, the Th17/Tc17 subsets display the highest PKM2 expression. Additionally, we observed a preferential inhibition of interferon-gamma (IFN-γ), interleukin-5 (IL-5), IL-13, and IL-17 production by MS T cells upon PKM2 pharmacological targeting. Finally, we found that PBMCs from patients with MS have a higher percentage of PKM2 monomer compared to PBMCs from HCs, supporting heightened PKM2 moonlighting activity.
interpretationOur data suggest that PKM2 may represent a therapeutic target to limit T cell-driven inflammation in MS and potentially other human autoimmune diseases.
fundingAustrian Multiple Sclerosis Research Society, Kulturamt der Stadt Graz, MEFOGraz and Worldwide Cancer Research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.